Last reviewed · How we verify

NCT05579392

A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis

Recruiting now NA Last updated 12 December 2025
What this trial tests

NA trial testing Bright Light Therapy in Inflammatory Bowel Disease in 30 participants. Currently enrolling.

Timeline
22 September 2022
Primary endpoint
1 May 2026
31 May 2026

Quick facts

Lead sponsorRush University Medical Center
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingsingle
Primary purposebasic science
Enrollment30
Start date22 September 2022
Primary completion1 May 2026
Estimated completion31 May 2026
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Rush University Medical Center

Who can join

18 and older, any sex, with Inflammatory Bowel Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Crohn's Disease (CD) and Ulcerative Colitis (UC), collectively known as inflammatory bowel disease (IBD), are two of the most significant chronic conditions of the gastrointestinal tract (GIT) and affects over 1.5 million individuals in the U.S. Recently, there has been an increased understanding of the importance of sleep and sleep disruption in IBD as a potentially modifiable risk factor. We, therefore, hypothesize that intervening with morning bright light therapy (BLT) in IBD patients with CM will decrease intestinal permeability and pro-inflammatory cytokines, positively impact intestinal microbiota, and improve quality of life (QoL).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Bright Light Therapy

Trials testing the same drug.

Other recruiting trials for Inflammatory Bowel Disease

Currently open trials in the same condition.

Other Rush University Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05579392.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing